INDV Earnings Date: Feb 25, 2027 (Estimated) — Indivior Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is INDV's next earnings date?
Indivior Pharmaceuticals Inc (INDV) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.19 on revenue of $336.6M.
How did INDV do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Indivior Pharmaceuticals Inc posted EPS of $1.32 versus the $1.06 estimate, a beat of 24.5%. Revenue was $356.0M against a $329.4M estimate. The stock's 1-day post-earnings move was +1.4%.
How much does INDV stock move after earnings?
INDV beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.9% (up or down) in the day after earnings.
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
🤖 AI Earnings Analysis
Indivior’s specialty-drug results were strong: revenue rose 13% year over year to $356M, beating estimates, while EPS reached $1.32 versus $1.06 expected. The reported 429% revenue growth is misleading; underlying growth supports a positive view.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.06 | 1.32 | +24.53% | $356.0M | ✅ Beat | +1.38% | — | — |
| 2026-08-03 | Q2 2026 | 0.92 | 1.15 | +25.00% | $343.0M | ✅ Beat | -6.60% | -2.97% | -12.70% |
| 2026-04-30 | Q1 2026 | 0.66 | 0.96 | +45.45% | $317.0M | ✅ Beat | +7.70% | +18.92% | +5.48% |
| 2026-02-26 | Q4 2025 | 0.66 | 0.82 | +24.24% | $358.0M | ✅ Beat | +0.24% | -4.37% | -10.94% |
| 2025-10-30 | Q3 2025 | 0.40 | 0.72 | +80.00% | $314.0M | ✅ Beat | +15.41% | +26.98% | +33.12% |
| 2025-07-31 | Q2 2025 | 0.26 | 0.51 | +96.15% | $302.0M | ✅ Beat | +16.09% | +26.44% | +37.24% |
| 2025-04-24 | Q1 2025 | 0.23 | 0.41 | — | $266.0M | ✅ Beat | +13.86% | +21.80% | +18.62% |
| 2025-02-20 | Q4 2024 | 0.26 | 0.32 | +23.08% | $298.0M | ✅ Beat | -17.60% | -21.36% | -11.27% |
Showing last 8 quarters.